Mylan and Theravance’s COPD treatment gets FDA approval

Mylan and Theravance’s COPD treatment gets FDA approval

(Reuters) – Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

The treatment, Yupelri here, is a once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough.

Yupelri belongs to a class of drugs called long-acting muscarinic antagonists (LAMA), with the existing treatment options primarily being hand-held devices such as Boehringer Ingelheim’s Spiriva.

Картинки по запросу revefenacin structure

The treatment is expected to be made available in the United States before the end of the year, Theravance and Mylan said in a statement.

About 9-10 percent of COPD patients in the United States prefer a nebulized product for maintenance therapy, Raymond James analyst Elliot Wilbur said in a note prior to the approval.

Baird Equity Research analyst Brian Skorney, who forecasts peak sales of more than $250 million for Yupelri in 2030, expects a tough launch for the treatment as the COPD market becomes increasingly complicated with branded and generic options.

“We think the opportunity for a nebulized LAMA is relatively limited by the treatment paradigm in COPD, where combination therapy is the mainstay and there is wide availability of numerous inhalers containing two-three mechanisms in one,” Skorney said in a note.

Sunovion Pharmaceuticals Inc’s Lonhala Magnair, the only other nebulized LAMA treatment, was approved here by the FDA late last year.

COPD is a collective term for a group of lung diseases commonly triggered by long-term smoking and exposure to air pollutants. The World Health Organization predicts COPD to become the third leading cause of death worldwide by 2030.

Mylan’s shares closed marginally down at $36.95 on Friday, while Theravance ended up 5.1 percent at $25.81.

NOVEMBER 9, 2018

https://www.reuters.com/

November 9, 2018 / Pharma News